Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone plus /- Rituximab ( CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

被引：0
|
作者：
Kouroukis, Tom [1 ]
Cheung, Winson Y. [2 ]
Abdel-Samad, Nizar [3 ]
Sehdev, Sandeep [4 ]
Poulin-Costello, Melanie [5 ]
Gillesby, Brad [5 ]
Robson, Ewan J. D. [5 ]
机构：
[1] Juravinski Canc Ctr, Hamilton, ON, Canada
[2] British Columbia Canc Agcy, Vancouver, BC, Canada
[3] Moncton Hosp, Moncton, NB, Canada
[4] William Osler Hlth Syst, Brampton, ON, Canada
[5] Amgen Canada Inc, Mississauga, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3038.3038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3038
引用
收藏
页数：6
相关论文
共 50 条
  • [31] THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study
    Niitsu, N
    Umeda, M
    LEUKEMIA, 1997, 11 (11) : 1817 - 1820
  • [32] THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin’s lymphoma in elderly patients: a prospective study
    N Niitsu
    M Umeda
    Leukemia, 1997, 11 : 1817 - 1820
  • [33] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma
    Lamar, Zanetta S.
    Fino, Nora
    Palmer, Jodi
    Gruber, Lindsey
    Morris, Bonny B.
    Raetskaya-Solntseva, Olga
    Kennedy, LeAnne
    Vaidya, Rakhee
    Hurd, David
    Zamkoff, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (02): : 76 - 81
  • [34] Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma
    Takano, H
    Sawada, K
    Sato, N
    Notoya, A
    Tarumi, T
    Hirayama, S
    Koizumi, K
    Takahashi, TA
    Sekiguchi, S
    Koike, T
    LEUKEMIA & LYMPHOMA, 1996, 21 (5-6) : 473 - 478
  • [35] Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma
    Sparano, JA
    Negassa, A
    Lansigan, E
    Locke, R
    De Silva, CR
    Wiernik, PH
    MEDICAL ONCOLOGY, 2005, 22 (03) : 257 - 267
  • [36] Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-hodgkin’s lymphoma
    Joseph A. Sparano
    Abdissa Negassa
    Erick Lansigan
    Robin Locke
    Chamath R. De Silva
    Peter H. Wiernik
    Medical Oncology, 2005, 22 : 257 - 267
  • [37] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma
    Tulpule, A
    Khan, AU
    Mohrbacher, AF
    Espina, BM
    Buchanan, L
    Berman, N
    Gorospe, G
    Boswell, WD
    Nathwani, BN
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 604S - 604S
  • [38] Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma
    N Yokose
    K Ogata
    H Tamura
    E An
    K Nakamura
    K Kamikubo
    S Kudoh
    K Dan
    T Nomura
    British Journal of Cancer, 1998, 77 : 2286 - 2290
  • [39] A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma
    Meyer, RM
    Gyger, M
    Langley, R
    Lespérance, B
    Caplan, SN
    LEUKEMIA & LYMPHOMA, 1998, 30 (5-6) : 591 - 600
  • [40] Combined therapy with rituximab plus cyclophosphamide/Vincristine/Prednisone for Sjogren's syndrome - associated B-Cell non-Hodgkin's lymphoma
    Carbone, J.
    Perez-Fernandez, R.
    Munoz, A.
    Sabin, P.
    Carreno, L.
    Fernandez-Cruz, E.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 34 (01) : 80 - 84
12345